Cassava Defends Alzheimer’s Drug Data After FDA Is Asked To Stop Trial

Biopharmaceutical company Cassava Sciences and antitrust law firm Labaton Sucharow are duking it out over the validity of clinical trial data for Cassava’s investigational Alzheimer’s drug simufilam. Labaton Sucharow Partner Jordan Thomas has petitioned FDA to put a halt on the drug’s clinical trial until the agency and the National Institutes of Health audit the data, but Cassava argues Thomas’ allegations questioning the scientific integrity of the data are false and misleading. FDA acknowledged it received the citizen petition Monday...